Natco Pharma

{
  "main_header": {
    "sid": 156274,
    "name": "Natco Pharma",
    "stock_name": "Natco Pharma",
    "full_name": "Natco Pharma Ltd.",
    "name_url": "stocks-analysis/natco-pharma",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "850.00",
    "chg": 12.15,
    "chgp": "1.45%",
    "dir": 1,
    "prev_price": "837.85",
    "mcapval": "15,224.34 Cr",
    "mcap": "Small Cap",
    "scripcode": 524816,
    "symbol": "NATCOPHARM",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "sector_id": 65,
    "indexname": "India SENSEX",
    "isin": "INE987B01026",
    "curr_date": "Sep 24, 10:43 AM",
    "curr_time": "10:44 AM",
    "last_traded_at": "Sep 24, 10:43 AM IST",
    "bse_nse_vol": "2.89 lacs",
    "exc_status": "Active",
    "traded_date": "Sep 24, 2026",
    "traded_date_str": "2026 09 24",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/natco-pharma-156274-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Natco Pharma Ltd. is Rated Sell by MarketsMOJO",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/natco-pharma-ltd-is-rated-sell-by-marketsmojo-4197985",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/9/NatcoPharmaLtd_mojoScore_4197985.png",
        "date": "2026-09-19 10:10:20",
        "description": "Natco Pharma Ltd. is rated Sell by MarketsMOJO, with this rating last updated on 04 August 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 19 September 2026, providing investors with an up-to-date view of the company’s performance and outlook."
      },
      {
        "title": "Natco Pharma Ltd. is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/natco-pharma-ltd-is-rated-sell-4186537",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/9/NatcoPharmaLtd_mojoScore_4186537.png",
        "date": "2026-09-08 10:10:25",
        "description": "Natco Pharma Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 04 August 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 08 September 2026, providing investors with the latest insights into the company’s performance and outlook."
      },
      {
        "title": "Natco Pharma Ltd. is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/natco-pharma-ltd-is-rated-sell-4171572",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/NatcoPharmaLtd_mojoScore_4171572.png",
        "date": "2026-08-27 10:10:03",
        "description": "Natco Pharma Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 04 August 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 27 August 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing."
      },
      {
        "title": "Natco Pharma Ltd. Technical Momentum Shifts Amid Bearish Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/natco-pharma-ltd-technical-momentum-shifts-amid-bearish-signals-4169282",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/NatcoPharmaLtd_technicaldot_4169282.png",
        "date": "2026-08-26 08:00:21",
        "description": "Natco Pharma Ltd., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, with key indicators signalling a bearish trend. The company’s share price has declined by 1.92% to ₹866.45, reflecting growing investor caution amid mixed technical signals and a downgrade in its Mojo Grade from Hold to Sell."
      },
      {
        "title": "Natco Pharma Ltd. Technical Momentum Shifts Amid Bearish Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/natco-pharma-ltd-technical-momentum-shifts-amid-bearish-signals-4160260",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/NatcoPharmaLtd_technicaldot_4160260.png",
        "date": "2026-08-19 08:00:30",
        "description": "Natco Pharma Ltd., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, with key indicators signalling a bearish trend. Despite a modest day gain of 1.16%, the company’s technical parameters reveal a complex picture, prompting a downgrade in its Mojo Grade from Hold to Sell as of 4 August 2026."
      },
      {
        "title": "Natco Pharma Ltd. Technical Momentum Shifts Amid Bearish Sentiment",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/natco-pharma-ltd-technical-momentum-shifts-amid-bearish-sentiment-4158475",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/NatcoPharmaLtd_technicaldot_4158475.png",
        "date": "2026-08-18 08:00:34",
        "description": "Natco Pharma Ltd., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, reflecting a complex interplay of bearish and mildly bullish signals. Recent technical parameter changes have prompted a downgrade in its Mojo Grade from Hold to Sell, underscoring growing investor caution amid subdued price action and mixed indicator readings."
      },
      {
        "title": "Natco Pharma Ltd. Faces Bearish Momentum Amid Technical Downgrade",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/natco-pharma-ltd-faces-bearish-momentum-amid-technical-downgrade-4156818",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/NatcoPharmaLtd_technicaldot_4156818.png",
        "date": "2026-08-17 08:00:17",
        "description": "Natco Pharma Ltd., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, with key indicators signalling a bearish trend. The company’s share price has declined sharply by 5.23% on 17 Aug 2026, reflecting growing investor caution amid mixed technical signals and a downgrade in its Mojo Grade from Hold to Sell."
      },
      {
        "title": "Natco Pharma Ltd. is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/natco-pharma-ltd-is-rated-sell-4156412",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/NatcoPharmaLtd_mojoScore_4156412.png",
        "date": "2026-08-16 10:10:17",
        "description": "Natco Pharma Ltd. is rated Sell by MarketsMOJO, with this rating last updated on 4 August 2026. While the rating was revised on that date, the analysis and financial metrics presented here reflect the stock's current position as of 16 August 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing."
      },
      {
        "title": "Natco Pharma Ltd. Technical Momentum Shifts Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/natco-pharma-ltd-technical-momentum-shifts-amid-mixed-market-signals-4150773",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/NatcoPharmaLtd_technicaldot_4150773.png",
        "date": "2026-08-13 08:00:13",
        "description": "Natco Pharma Ltd., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a subtle shift in its technical momentum, reflecting a complex interplay of bearish and mildly bullish signals across key indicators. Despite a recent downgrade from Hold to Sell by MarketsMOJO, the stock’s price action and technical parameters suggest a nuanced outlook for investors navigating this evolving landscape."
      }
    ],
    "total": 5680,
    "sid": "156274",
    "stock_news_url": "https://www.marketsmojo.com/news/natco-pharma-156274"
  },
  "announcements": [
    {
      "caption": "Board Meeting Intimation for Rights Issue Of Equity Shares",
      "datetime": "22-Sep-2026",
      "details": "Natco Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/09/2026 inter alia to consider and approve to consider discuss and decide various matters in connection with the Rights Issue including the specific terms of the Rights Issue such as the determination of the Rights Issue price and related payment mechanism rights entitlement ratio the record date and timing of the Rights Issue",
      "source": "BSE"
    },
    {
      "caption": "Receipt Of In-Principal Approval For Rights Issue Of Equity Shares",
      "datetime": "21-Sep-2026",
      "details": "Receipt of In-principal approval for Rights Issue of Equity Shares",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Outcome for Outcome Of Board Meeting",
      "datetime": "09-Sep-2026",
      "details": "Outcome of Board Meeting",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Natco Pharma Ltd. has declared <strong>75%</strong> dividend, ex-date: 20 Aug 26",
          "dt": "2026-08-20",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Natco Pharma Ltd. has announced <strong>2:10</strong> stock split, ex-date: 26 Nov 15",
          "dt": "2015-11-26",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Natco Pharma Ltd. is Rated Sell by MarketsMOJO

2026-09-19 10:10:20

Natco Pharma Ltd. is rated Sell by MarketsMOJO, with this rating last updated on 04 August 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 19 September 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Read full news article

Natco Pharma Ltd. is Rated Sell

2026-09-08 10:10:25

Natco Pharma Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 04 August 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 08 September 2026, providing investors with the latest insights into the company’s performance and outlook.

Read full news article

Natco Pharma Ltd. is Rated Sell

2026-08-27 10:10:03

Natco Pharma Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 04 August 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 27 August 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Read full news article

Natco Pharma Ltd. Technical Momentum Shifts Amid Bearish Signals

2026-08-26 08:00:21

Natco Pharma Ltd., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, with key indicators signalling a bearish trend. The company’s share price has declined by 1.92% to ₹866.45, reflecting growing investor caution amid mixed technical signals and a downgrade in its Mojo Grade from Hold to Sell.

Read full news article

Natco Pharma Ltd. Technical Momentum Shifts Amid Bearish Signals

2026-08-19 08:00:30

Natco Pharma Ltd., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, with key indicators signalling a bearish trend. Despite a modest day gain of 1.16%, the company’s technical parameters reveal a complex picture, prompting a downgrade in its Mojo Grade from Hold to Sell as of 4 August 2026.

Read full news article

Natco Pharma Ltd. Technical Momentum Shifts Amid Bearish Sentiment

2026-08-18 08:00:34

Natco Pharma Ltd., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, reflecting a complex interplay of bearish and mildly bullish signals. Recent technical parameter changes have prompted a downgrade in its Mojo Grade from Hold to Sell, underscoring growing investor caution amid subdued price action and mixed indicator readings.

Read full news article

Natco Pharma Ltd. Faces Bearish Momentum Amid Technical Downgrade

2026-08-17 08:00:17

Natco Pharma Ltd., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, with key indicators signalling a bearish trend. The company’s share price has declined sharply by 5.23% on 17 Aug 2026, reflecting growing investor caution amid mixed technical signals and a downgrade in its Mojo Grade from Hold to Sell.

Read full news article

Natco Pharma Ltd. is Rated Sell

2026-08-16 10:10:17

Natco Pharma Ltd. is rated Sell by MarketsMOJO, with this rating last updated on 4 August 2026. While the rating was revised on that date, the analysis and financial metrics presented here reflect the stock's current position as of 16 August 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Read full news article

Natco Pharma Ltd. Technical Momentum Shifts Amid Mixed Market Signals

2026-08-13 08:00:13

Natco Pharma Ltd., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a subtle shift in its technical momentum, reflecting a complex interplay of bearish and mildly bullish signals across key indicators. Despite a recent downgrade from Hold to Sell by MarketsMOJO, the stock’s price action and technical parameters suggest a nuanced outlook for investors navigating this evolving landscape.

Read full news article

View All News